Healthcare
Live Price
Offline$15.97
+0.31% today
1Y Change
+537.82%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rallybio Corporation (RLYB) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $15.97 and up 537.8% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +34.9%, EPS growth of +85.1%, a dividend yield of 0.0%. What stands out right now is revenue +34.9%, EPS +85.1%, free cash flow +39.5% with operating margin -3853.6% and ROIC -56.9%. Valuation already assumes a fairly strong business story at price/sales 58.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RLYB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLYB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RLYB Max Drawdown
-31.05%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RLYB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$47.0M
+29.5% YoY
Free Cash Flow
-$45.9M
+20.0% YoY
Revenue Growth
+34.9%
EPS Growth
+85.1%
Gross Margin
99.7%
Net Margin
-1046.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 858K | 636K | 0 | 0 | 0 |
| Gross Profit | 766K | 636K | -150K | -167K | -109K |
| Operating Income | -28M | -60M | -79M | -68M | -46M |
| EBITDA | -28M | -60M | -79M | -68M | -45M |
| Net Income | -9M | -58M | -75M | -67M | -47M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31M | 14M | 24M | 57M | 175M |
| Total Assets | 62M | 68M | 116M | 180M | 182M |
| Total Liabilities | 4M | 6M | 9M | 11M | 7M |
| Shareholder Equity | 58M | 62M | 106M | 169M | 176M |
| Total Debt | 176K | 154K | 392K | 555K | 0 |
| Net Debt | -31M | -14M | -24M | -56M | -175M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
46M
+20.5% YoY
Capital Expenditures
333K
-516.7% YoY
Free Cash Flow
46M
+20.0% YoY
Key ratios
Gross Margin
99.7%
Operating Margin
-3853.6%
Net Margin
-1046.4%
ROE
-16.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.